Edition:
India

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

6.57CAD
10:00pm IST
Change (% chg)

$-0.34 (-4.85%)
Prev Close
$6.91
Open
$6.70
Day's High
$6.76
Day's Low
$6.52
Volume
192,395
Avg. Vol
269,975
52-wk High
$8.88
52-wk Low
$6.52

Summary

Name Age Since Current Position

James Gale

69 2017 Independent Chairman of the Board

Samira Sakhia

2017 President, Chief Financial Officer, Director

Jonathan Goodman

48 2013 Chief Executive Officer, Director

Amal Khouri

2014 Vice President - Business Development

Jody Engel

Director - Business Development

Arvind Utchanah

2016 Director of Finance

Meir Jakobsohn

2015 Director

Nancy Harrison

2018 Independent Director

Robert Lande

54 2013 Independent Director

Sylvie Tendler

2014 Independent Director

Michael Tremblay

2019 Independent Director

Biographies

Name Description

James Gale

Mr. James C. Gale is Independent Chairman of the Board of the Company. Mr. Gale is the founding partner of Signet Healthcare Partners (“Signet”). He is currently the Chairman of the Board of Alpex Pharma S.A. and Teligent Inc., and also serves on the board of directors of Spepharm BV, Bionpharma Inc., CoreRx, Inc., Leon Nanodrugs GmbH, Pharmaceutics International, Inc. and Chr. Olesen Synthesis A/S. Prior to Signet, Mr. Gale worked for Gruntal & Co., LLC (“Gruntal”) as head of principal investment activities and investment banking. Prior to joining Gruntal, he worked for Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co. Mr. Gale holds an M.B.A. from the University of Chicago. Mr. Gale was on the board of directors of Paladin from 2008 to 2014.

Samira Sakhia

Ms. Samira Sakhia, CPA, is President, Chief Financial Officer, Director of the Company. Ms. Sakhia joined Knight as President in August 2016 and assumed the additional responsibility of CFO in October 2017. Prior to Knight, Ms. Sakhia served as the CFO at Paladin Labs Inc. from 2001 to 2015. At Paladin Labs Inc., Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin Labs Inc., Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. In addition, Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin Labs Inc. to Endo Health Solutions Inc. for over $3 billion. Ms. Sakhia holds an MBA and a Bachelors of Commerce degree from McGill University and is also a Chartered Professional Accountant. Ms. Sakhia currently serves on the boards of Crescita Therapeutics Inc. and Profound Medical Corporation. In addition, Ms. Sakhia serves on the board of the Montreal Society for the Prevention of Cruelty to Animals, the International Advisory Board of McGill’s Desautels Faculty of Management, is an independent Board member at the McGill University Health Center, and is a member of the Board of Governors of McGill University.

Jonathan Goodman

Mr. Jonathan Ross Goodman is Chief Executive Officer, Director of the Company. Mr. Goodman founded Knight in February 2014. Prior to Knight, Mr. Goodman was the co-founder, President and CEO of Paladin Labs Inc. which was acquired by Endo Health Solutions Inc. (“Endo”) for $3.2 billion. Under his leadership, $1.50 invested in Paladin Labs Inc. at its founding was worth $151 nineteen years later. Prior to co-founding Paladin Labs Inc. in 1995, Mr. Goodman was a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman currently serves on the board of directors of Medison Biotech (1995) Ltd. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honours. Additionally, Mr. Goodman holds an LL.B. and an M.B.A. from McGill University.

Amal Khouri

Ms. Amal Khouri is Vice President - Business Development of the Company. Ms. Khouri joined Knight as Vice-President of Business Development in August 2014. Prior to Knight, Ms. Khouri worked at Novartis Pharma for over 7 years, where she held multiple positions within the global business development and licensing team in Basel, Switzerland. Before joining Novartis, she worked in business development at Paladin Labs Inc. in roles with increasing responsibilities. In addition, Ms. Khouri serves on the board of Antibe Therapeutics Inc.

Jody Engel

Ms. Jody Engel is Director - Business Development of the company.

Arvind Utchanah

Mr. Arvind Utchanah is Director - Finance of the company.

Meir Jakobsohn

Mr. Meir Jakobsohn is Director of the Company. Mr. Jakobsohn is the CEO of Israeli-based Medison Biotech (1995) Ltd. (“Medison”) which he founded in 1996 and spearheaded to becoming a leading Israeli pharmaceutical distributor. Formerly, he served as the Chief Operating Officer of M. Jakobsohn Ltd., a pioneer in opening the Israeli market to global pharmaceutical companies like Ciba-Geigy (Novartis), which it represented between 1937 and 1995.

Nancy Harrison

Ms. Nancy Harrison is Independent Director of the Company. Ms. Harrison is co-founder and former President of MSI Methylation Sciences, a private venture backed development company with a novel treatment of depression in a Phase II clinical trial. She is a former Partner and Senior Vice President of Ventures West Management Inc. Ms. Harrison spent 13 years with Ventures West leading its life sciences practice in Canada and the U.S. She is one of the most experienced life sciences investors in the Canadian venture capital industry and was instrumental in Ventures West’s involvement in the sector and with companies such as Angiotech Pharmaceuticals Inc., AnorMed Inc., Salmedix Inc., Oncogenix Pharmaceuticals Inc., Celator Pharmaceuticals Inc., and Caprion BioSciences. During her time with Ventures West, the firm grew from approximately $80 million to over $750 million.

Robert Lande

Mr. Robert N. Lande is Independent Director of the Company. Mr. Lande is the President of FXCM Group LLC, an online brokerage firm offering trading in foreign exchange, equity indices and commodities. Formerly, he was Chief Financial Officer of FXCM and prior to that was a managing partner and Chief Operating Officer of Riveredge Capital Partners LLC (“Riveredge”), an investment management firm. Prior to Riveredge, Mr. Lande worked for over 16 years within the BCE/Bell Canada group where his last position was Chief Financial Officer of Telecom Américas Ltd., a joint venture between Bell Canada International, AT&T (then SBC Communications) and America Movil. Mr. Lande is a chartered financial analyst and holds an M.B.A. from the John Molson School of Business and a B.A. in Economics from McGill University.

Sylvie Tendler

Ms. Sylvie Tendler is Independent Director of the Company. Ms. Tendler is a leading pharmaceutical market research specialist. In 2001, she founded The Tendler Group, a custom medical marketing research company, which served 12 of the Top 20 global pharmaceutical companies. In 2007, the company was acquired by IntrinsiQ LLC (owned at the time by Accel-KKR). Ms. Tendler stayed through 2010 to oversee the managerial transition following the acquisition. Ms. Tendler has hands-on experience conducting global primary research in Canada, the U.S., the top 5 EU markets, as well as Brazil and Mexico, and has been involved in the development and launch of blockbuster prescription products across several therapeutic categories.

Michael Tremblay

Mr. Michael J. Tremblay is Independent Director of the Company. Mr. Tremblay has over 40 years of experience in the Canadian pharmaceutical industry, and was most recently President of Astellas Pharma Canada, Inc. until his retirement in March of 2018. Mr. Tremblay also served on the board of Innovative Medicines Canada, the Canadian pharmaceutical industry organization representing innovative, research based pharmaceutical companies, from 2011 and was elected Chair of the Board for a term of two years starting in 2015. Prior to Astellas Canada, Mr. Tremblay held various commercial positions at Janssen Canada Inc., Searle Canada Inc. Baxter-Travenol Canada, Inc. and Smith, Kline & French Canada, Inc.

Basic Compensation

Name Fiscal Year Total

James Gale

87,029

Samira Sakhia

786,564

Jonathan Goodman

994,692

Amal Khouri

614,813

Jody Engel

295,718

Arvind Utchanah

267,780

Meir Jakobsohn

--

Nancy Harrison

55,959

Robert Lande

96,236

Sylvie Tendler

82,653

Michael Tremblay

--
As Of  31 Dec 2018